Lilly to acquire Merida Biosciences in deal worth up to USD 2.88 billion

• Eli Lilly agreed to acquire Merida Biosciences for up to USD 2.88 billion in cash, including upfront and milestone payments.
• Deal adds Merida’s antibody-degradation platform aimed at selectively removing disease-causing antibodies while preserving normal immune function.
• Lead asset MER511 is in Phase 1 for Graves’ disease, thyroid eye disease; early data showed robust reductions in pathogenic antibodies.
• Pipeline also includes preclinical MER769 for allergic diseases, with earlier-stage programs targeting kidney and other immune-mediated conditions.
• Closing is expected in the fourth quarter of 2026, subject to regulatory approvals and other customary conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608310645PR_NEWS_USPR_____DE36645) on August 31, 2026, and is solely responsible for the information contained therein.